<DOC>
	<DOCNO>NCT02857244</DOCNO>
	<brief_summary>The study team propose treat Parkinson 's patient gait difficulty multidisciplinary approach medication . Single medication treatment , use cholinergic-boosting anti-dementia medication target cholinergic deficiency improve executive dysfunction attention deficit , use medication boost norepinephrine system , proven effective far treat gait difficulty . Anti-anxiety medication , particularly SNRI ( serotonin norepinephrine reuptake inhibitor ) medication , also ameliorate norepinephrinergic deficiency , study except one successful case report use duloxetine treat primary progressive freezing gait . Targeting multiple mechanism time , combination SNRI antianxiety medication ( also boost norepinephrine system , duloxetine ) anti-dementia medication correct cholinergic deficiency ( donepezil ) , target new mechanism , use anti-GABAergic medication target area responsible gait sleep cycle ( pedunculopontine nucleus area , PPNa ) try . Therefore , collaboration multidisciplinary team among neurology movement disorder team cognition sleep team , psychiatry team essential , tried study treat challenge gait difficulty Parkinson patient .</brief_summary>
	<brief_title>A Multidisciplinary Approach Manage Gait Difficulty Parkinson Patients</brief_title>
	<detailed_description>The study team propose treat parkinsonian patient gait difficulty FOG SNRI anti-anxiety medication duloxetine 4 week , follow additional anti-dementia medication donepezil 2 week determine whether antianxiety treatment alone combination anti-dementia medication improve gait . Another medication GABA antagonist property target gait control area PPNa ( improve anxiety cognition well ) , modafinil , try 2 week 4-week washout period previous medication . Specifically , investigator propose open label prospective pilot study use duloxetine treat 22 parkinsonian patient FOG , aim estimate 80 % power detect 50 % . Each patient take duloxetine 30mg 1 week , follow 60mg qam 1 week , 90mg qam 1 week , 120mg qam 1 week , tolerate . The patient take duloxetine total 4 week , describe . The dose duloxetine reduce patient tolerate high rank dose designate . This principle apply two medication use study well . Donepezil add duloxetine 120mg qam ( high dose patient tolerate lower 120mg ) 5mg qd 1 week , follow 10mg qd 1 week . Each patient visit u 3 time ( baseline end medication , namely 4 week duloxetine 2 week donepezil ) , check UPDRS-III ( PSP scale well PSP patient ) , stand-walk-sit , freeze gait questionnaire , Montreal cognitive scale ( MoCA ) patient Donepezil treatment , anxiety scale patient duloxetine treatment ( patient dopaminergic medication ) . Daily fall , freeze gait ( questionnaire ) quality life ( PDQ-39 scale ) past week prior clinical visit also check . After 4-week washout period , patient take modafinil 100mg qam 1 week , follow 200mg qam 1 week . Each patient visit u twice ( baseline end 4-week washout period , end 2-week modafinil treatment ) , check UPDRS ( PSP scale well PSP patient ) , stand-walk-sit , freeze gait questionnaire , MoCA , anxiety scale Epworth sleep scale visit 1 hour dopaminergic medication ( ) ( patient dopaminergic medication ) . Daily fall , freeze gait quality life ( PDQ-39 ) past week prior clinical visit also check . A paired t-test use compare change regimen baseline , primary outcome gait difficulty FOG frequency severity , secondary outcome anxiety , cognition , UPDRS-III ( plus PSP scale PSP patient ) , Epworth sleep scale ( modafinil trial ) dopaminergic medication ( stay dopaminergic medication night ) ( 1 hour take dopaminergic medication ) state quality life assessment . The investigator want see medication different work mechanism , along combination , could improve FOG motor symptom , improvement anxiety , cognitive dysfunction waken state dopaminergic medication ( parkinsonism ) state state .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Parkinsonian patient Parkinson 's disease per UK brain bank criterion 15 , PSP per SPSPNINDS criterion 16 , FOG dopaminergic medication . Patients psychosis , unable walk without assistance , seizure , allergy three medication trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Freezing Gait</keyword>
</DOC>